TTD | Drug: D0N5OV

Drug General Information
Drug ID	D0N5OV
Former ID	DAP000394
Drug Name	Cetuximab
Synonyms	Erbitux; Cetuximab (genetical recombination); Erbitux (TN); Cetuximab (USAN/INN); Cetuximab (genetical recombination) (JAN); novel EGFR mAb inhibitors
Drug Type	Antibody
Indication	Colorectal cancer [ICD9: 153, 154; ICD10:C18-C21]		Approved	[527466], [541939]
Therapeutic Class	Anticancer Agents
Company	Bristol-Myers Squibb
Formula	C6484H10042N1732O2023S36
CAS Number	CAS 205923-56-4
PubChem Substance ID	17397595
SuperDrug ATC ID	L01XC06
Drug Resistance Mutation (DRM)
DRM	DRM Info
Target and Pathway
Target(s)	Epidermal growth factor receptor	Target Info		[535397], [535602], [535628]
KEGG Pathway	MAPK signaling pathway
	ErbB signaling pathway
	Ras signaling pathway
	Rap1 signaling pathway
	Calcium signaling pathway
	Cytokine-cytokine receptor interaction
	HIF-1 signaling pathway
	FoxO signaling pathway
	Endocytosis
	PI3K-Akt signaling pathway
	Dorso-ventral axis formation
	Focal adhesion
	Adherens junction
	Gap junction
	Regulation of actin cytoskeleton
	GnRH signaling pathway
	Estrogen signaling pathway
	Oxytocin signaling pathway
	Epithelial cell signaling in Helicobacter pylori infection
	Hepatitis C
	Pathways in cancer
	Proteoglycans in cancer
	MicroRNAs in cancer
	Pancreatic cancer
	Endometrial cancer
	Glioma
	Prostate cancer
	Melanoma
	Bladder cancer
	Non-small cell lung cancer
	Central carbon metabolism in cancer
	Choline metabolism in cancer
NetPath Pathway	IL4 Signaling Pathway
NetPath Pathway	EGFR1 Signaling Pathway
PANTHER Pathway	Cadherin signaling pathway
PANTHER Pathway	EGF receptor signaling pathway
Pathway Interaction Database	LPA receptor mediated events
	Signaling events mediated by PTP1B
	Arf6 signaling events
	Signaling events mediated by TCPTP
	Thromboxane A2 receptor signaling
	SHP2 signaling
	Regulation of Telomerase
	EGF receptor (ErbB1) signaling pathway
	EGFR-dependent Endothelin signaling events
	Posttranslational regulation of adherens junction stability and dissassembly
	Direct p53 effectors
	ErbB1 downstream signaling
	Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
	E-cadherin signaling in keratinocytes
	ErbB receptor signaling network
	Internalization of ErbB1
	Stabilization and expansion of the E-cadherin adherens junction
	a6b1 and a6b4 Integrin signaling
	Syndecan-3-mediated signaling events
Reactome	Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
	SHC1 events in ERBB2 signaling
	PLCG1 events in ERBB2 signaling
	PIP3 activates AKT signaling
	GRB2 events in EGFR signaling
	GAB1 signalosome
	SHC1 events in EGFR signaling
	EGFR downregulation
	GRB2 events in ERBB2 signaling
	PI3K events in ERBB2 signaling
	EGFR Transactivation by Gastrin
	Constitutive Signaling by Aberrant PI3K in Cancer
	Constitutive Signaling by EGFRvIII
	RAF/MAP kinase cascade
WikiPathways	ErbB Signaling Pathway
	Regulation of Actin Cytoskeleton
	EGF/EGFR Signaling Pathway
	MAPK Signaling Pathway
	Focal Adhesion
	Aryl Hydrocarbon Receptor Pathway
	Extracellular vesicle-mediated signaling in recipient cells
	TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer
	Hair Follicle Development: Cytodifferentiation (Part 3 of 3)
	Bladder Cancer
	Hair Follicle Development: Induction (Part 1 of 3)
	Signaling by ERBB4
	Signaling by ERBB2
	Gastrin-CREB signalling pathway via PKC and MAPK
	PIP3 activates AKT signaling
	Nanoparticle-mediated activation of receptor signaling
	Aryl Hydrocarbon Receptor
	Spinal Cord Injury
	Integrated Pancreatic Cancer Pathway
	Gastric cancer network 2
	AGE/RAGE pathway
	Signaling Pathways in Glioblastoma
	Arylhydrocarbon receptor (AhR) signaling pathway
	miR-targeted genes in muscle cell - TarBase
	miR-targeted genes in lymphocytes - TarBase
	miR-targeted genes in epithelium - TarBase
	Integrated Breast Cancer Pathway
	Signaling by EGFR
	L1CAM interactions
References
Ref 527466	2004 approvals: the demise of the blockbuster. Nat Rev Drug Discov. 2005 Feb;4(2):93-4.
Ref 541939	(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6882).
Ref 535397	Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin Oncol. 2002 Feb;29(1 Suppl 4):27-36.
Ref 535602	Epidermal growth factor receptor-targeted therapy for pancreatic cancer. Semin Oncol. 2002 Oct;29(5 Suppl 14):31-7.
Ref 535628	Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade. Mol Cancer Ther. 2002 May;1(7):507-14.

Drug Information